Clinical Trials Directory

Trials / Completed

CompletedNCT00292825

Effect of Closed Loop Pacemaker Treatment on Recurrent Vasovagal Syncope

SCANdinavian Vasovagal SYNCope Pacemaker Investigation (SCANSYNC)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Aarhus University Hospital Skejby · Academic / Other
Sex
All
Age
25 Years
Healthy volunteers
Not accepted

Summary

The main purpose is to prevent syncope in patients with recurrent syncopal episodes caused by malignant vasovagal faints and bradycardia. Patients are treated by a special pacemaker (closed loop stimulation \[CLS\]) which can potentially identify an incipient attack and prevent syncope by pacing.

Detailed description

The treatment of patients with recurrent syncope of vasovagal origin, not precipitated by usual vasovagal factors, and not associated with structural heart disease, is unsolved. The limitations of the conducted 5 pacemaker studies are a significant placebo effect of pacemaker treatment, underpowering and lack of double blinding. The pacemaker intervention has been accelerated dual chamber pacing at the time of bradycardia, which may be too late. However, a pooling of all data indicate a beneficial effect of pacing. Vasodilatation is an obligate element of all vasovagal syncopal episodes and in many also an early sign associated with the hyperkinetic empty left ventricle which triggers the reflex wave. The principle in closed loop stimulation (CLS) is a continuous surveillance of the impedance in the right ventricle which correlates highly with myocardial contractility. When contractility is increased significantly atrial pacing with prolonged AV delay is commenced. This principle has been used in chronotropic incompetent patients and in one small study of patients with vasovagal syncope with a positive outcome. The hypothesis is that the CLS will potentially identify an incipient vasovagal attack and be able to prevent the drop in cardiac output and bradycardia by early accelerated pacing. Patients will be treated 12 months with active pacing (CLS) and then crossed over to 12 months with passive pacing (VVI, 30 bpm). The study will be double blinded, only a technician will know the status of the pacemaker.

Conditions

Interventions

TypeNameDescription
DEVICEPacemaker treatment, pacemaker programmed as active = CLSPacemaker treatment with closed loop function(CLS)
DEVICEPacemaker, programmed as passive = VVI 30 beats per minute (bpm)pacemaker treatment as VVI 30 bpm

Timeline

Start date
2006-02-01
Primary completion
2010-03-01
Completion
2010-03-01
First posted
2006-02-16
Last updated
2010-04-01

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT00292825. Inclusion in this directory is not an endorsement.